Ketoconazole treatment in Cushing's syndrome: experience in 34 patients
- 1 October 1991
- journal article
- Published by Wiley in Clinical Endocrinology
- Vol. 35 (4) , 347-352
- https://doi.org/10.1111/j.1365-2265.1991.tb03547.x
Abstract
Summary. objective Ketoconazole treatment of Cushing's syndrome has been reported in single cases and a few small groups of 5–8 patients. We report our experience in 34 patients. design Clinical study, with pretreatment and post-treatment evaluations. patients Out of 67 patients with Cushing's syndrome admitted during the last 6 years, 34 (28 females/six males; age range 14–67 years) received ketoconazole as a palliative treatment due to severe clinical conditions or management of the disease while awaiting results of definitive therapy. measurements Urinary cortisol, plasma cortisol and ACTH, and routine chemistry were measured every week for 4 weeks, and then once a month. results Comparing the last values (mean±SEM) during treatment with baseline, urinary cortisol decreased from 1296.176 to 270.69 nmol/d (n=34; p=<.001); plasma cortisol decreased from 672 . 31 to 549 ± 35 nmol/1 (n= 34; p < 0.001). For patients with pituitary-dependent Cushing's syndrome, urinary cortisol decreased from 1073.126 to 200.21 nmol/d (n=28; pn=26; not significant). Twelve patients were treated for more than 6 months, and those with pituitary-dependent disease all received pituitary radiation therapy, except the two who eventually escaped pharmacological control. One additional patient with adrenal carcinoma and one with ectopic ACTH syndrome showed lack of control of urinary cortisol levels. Ketoconazole was withdrawn within the first week In two patients for allergic reaction and acute liver toxicity. Other side-effects Included: asymptomatic liver function abnormalities In three patients; gastrointestinal symptoms in four; worsening of gynaecomastia In one. Rapid clinical Improvement was observed together with the normalization of urinary cortisol levels, with regression of symptoms such as diabetes mellitus, hypertension, hypokalaemia, and restoration of well being. conclusions These data confirm that ketoconazole is valuable In the management of hypercortlsolism, provided that patients are closely watched to exclude those who may develop liver toxicity and to prevent the occurrence of adrenal Insufficiency.Keywords
This publication has 18 references indexed in Scilit:
- Use of ketoconazole in the treatment of Cushing's disease and ectopic ACTH syndromeClinical Endocrinology, 1991
- Ketoconazole: A New Type of Agent in the Treatment of Hypercholesterolemia?Hormone and Metabolic Research, 1990
- Successful treatment with ketoconazole of Cushing's syndrome in pregnancyPublished by Oxford University Press (OUP) ,1990
- CLINICAL EXPERIENCE WITH KETOCONAZOLE AS A THERAPY FOR PATIENTS WITH CUSHING'S SYNDROMEClinical Endocrinology, 1987
- RESPONSE OF PITUITARY‐ADRENAL AXIS TO CORTICOTROPHIN RELEASING HORMONE IN PATIENTS WITH CUSHING'S DISEASE BEFORE AND AFTER KETOCONAZOLE TREATMENTClinical Endocrinology, 1987
- The Use of Ketoconazole as an Inhibitor of Steroid ProductionNew England Journal of Medicine, 1987
- Ketoconazole-associated hepatic injuryJournal of Hepatology, 1986
- Ketoconazole. Use in the treatment of ectopic adrenocorticotropic hormone production and Cushing's syndrome in small-cell lung cancerArchives of internal medicine (1960), 1985
- KETOCONAZOLE THERAPY IN CUSHING'S DISEASEThe Lancet, 1985
- PROLONGED REMISSION IN FLORID CUSHING'S SYNDROME FOLLOWING METYRAPONE TREATMENTClinical Endocrinology, 1981